Advertisement

Antirheumatika und Antiphlogistika

  • Rainer H. Böger
  • Gerhard Schmidt

Zusammenfassung

Bei den Verordnungen der Antirheumatika und Antiphlogistika dominieren auch 2013 mit klarem Abstand die nichtsteroidalen Antiphlogistika. Unter diesen steht Ibuprofen weiterhin an erster Stelle vor Diclofenac in der Verordnungshäufigkeit. Die Verordnungen der zwei auf dem Markt verbliebenen selektiven Cyclooxygenase- 2-Hemmer sind erneut gegenüber dem Vorjahr angestiegen. Insgesamt machen die COX-2-Hemmstoffe auch 2013 jedoch nur gut 10% der Gesamtverordnungen in diesem Indikationsgebiet aus.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (2004): „Aus der UAW-Datenbank“: Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequenzen für ihre künftige Verordnung. Dtsch Ärztebl 101: A 3365Google Scholar
  2. Bannwarth B, Richez C (2011): Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 10: 123–131PubMedCrossRefGoogle Scholar
  3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528PubMedCrossRefGoogle Scholar
  4. Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1–15PubMedCrossRefGoogle Scholar
  5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102Google Scholar
  6. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al (2001): Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53: 343–353PubMedCrossRefGoogle Scholar
  7. Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781PubMedCrossRefGoogle Scholar
  8. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110PubMedCrossRefGoogle Scholar
  9. Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 86–9CrossRefGoogle Scholar
  10. Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421PubMedCrossRefGoogle Scholar
  11. Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581–1582PubMedGoogle Scholar
  12. DeAngelis CD, Fontanarosa PB (2008): Impugning the integrity of medical science. The adverse effects of industry influence. JAMA 299: 1833–1835PubMedGoogle Scholar
  13. DeWitt DL (1999): Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625–631PubMedGoogle Scholar
  14. Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). PflÜgers Arch 76: 306–318CrossRefGoogle Scholar
  15. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106–2111PubMedGoogle Scholar
  16. Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321: 181–190PubMedCrossRefGoogle Scholar
  17. European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea.eu.int/htms/hotpress/d6275705.htmGoogle Scholar
  18. European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdfGoogle Scholar
  19. European Medicines Agency (2012): European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. Press release 19.1–0.2012Google Scholar
  20. FDA Alert for Healthcare Professionals (2005): Valdecoxib (marketed as Bextra). Publiziert am 7. April 2005 unter: www.fda.gov/bbs/topics/news/2005/NEW01171.htmlGoogle Scholar
  21. FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html
  22. Food and Drug Administration (2004): FDA Public Health Advisory: Safety of Vioxx. Publiziert am 30. September 2004 unter: www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm
  23. Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C (2009): Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: A nationwide cohort study. Clin Pharmacol Ther 85: 190–19CrossRefGoogle Scholar
  24. Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740PubMedGoogle Scholar
  25. Gemeinsamer Bundesausschuss (2012): Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über die Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III Nummer 18 – Antiphlogistika oder Antirheumatika in fixer Kombination mit anderen Wirkstoffen vom 22. November 2012. Internet: http://www.g-ba.de/downloads/40-268-2120/2012-11-22_AM-RL3_Nr18-Antirheumatika_TrG.pdf
  26. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005): Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481PubMedCrossRefGoogle Scholar
  27. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262PubMedCrossRefGoogle Scholar
  28. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo- oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit J Pharmacol 123: 927–935CrossRefGoogle Scholar
  29. Hawkey CJ (1999): COX-2 inhibitors. Lancet 353: 307–314PubMedCrossRefGoogle Scholar
  30. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 43: 370–377PubMedCrossRefGoogle Scholar
  31. Hernández-Diaz S, Varas-Lorenzo C, Garcia Rodríguez LA (2006): Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266–274PubMedCrossRefGoogle Scholar
  32. Jüni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J 324: 1287–1288PubMedCentralPubMedCrossRefGoogle Scholar
  33. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005): Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157–164PubMedCrossRefGoogle Scholar
  34. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776–783PubMedCrossRefGoogle Scholar
  35. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075–1052Google Scholar
  36. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929–1933PubMedCrossRefGoogle Scholar
  37. Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324–326Google Scholar
  38. Mc Gettigan P, Henry D (2006): Cardiovascular risk and inhibition of cyclooxygenase: a systemic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633–1644Google Scholar
  39. Meyer R (2005): Pfizer nimmt Bextra vom Markt. Dtsch Ärztebl 102: A 1023Google Scholar
  40. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693–11697PubMedCentralPubMedCrossRefGoogle Scholar
  41. Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959PubMedCrossRefGoogle Scholar
  42. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005): Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091PubMedCrossRefGoogle Scholar
  43. Patel AM, Moreland LW (2010): Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4: 263–278PubMedCentralPubMedGoogle Scholar
  44. Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxygenase- 2 in gastric mucosal defense. Life Sci 69: 2993–3003PubMedCrossRefGoogle Scholar
  45. Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: www.akdae.de/20/40/Archiv/2007/40-20071011.pdfGoogle Scholar
  46. Prescrire international 2010: Rheumatoid arthritis: choice of antirheumatic treatment. Prescrire international 19: 30–34Google Scholar
  47. Psaty BM, Kronmal RA (2008): Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. A case study based on documents from rofecoxib litigation. JAMA 299: 1813–1817PubMedGoogle Scholar
  48. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759–766PubMedCentralPubMedCrossRefGoogle Scholar
  49. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008): Guest authorship and ghostwriting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. JAMA 299: 1800–1812PubMedGoogle Scholar
  50. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Petersen C, Gislason GH (2011): Duration of treatment with nonsteroidal anti-inflammatory drugs and impact of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226–2235PubMedCrossRefGoogle Scholar
  51. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group (2004): Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674Google Scholar
  52. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K (2010a): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 1. Dtsch Ärztebl 107: 279–285Google Scholar
  53. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD (2010b): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 2. Dtsch Ärztebl 107: 295–301Google Scholar
  54. Shi S, Klotz U (2008): Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233–252PubMedGoogle Scholar
  55. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000): Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284: 1247–1255PubMedCrossRefGoogle Scholar
  56. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA (2010): A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42: 711–714PubMedCrossRefGoogle Scholar
  57. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509PubMedCentralPubMedGoogle Scholar
  58. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080PubMedGoogle Scholar
  59. Solomon DH, Schneeweiss S, Glynn RJ, Kiota Y, Levin R, Mogun H, Avorn J (2004): Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073PubMedCrossRefGoogle Scholar
  60. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011): Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta- analysis. Brit Med J 342: c 7086 1–11Google Scholar
  61. Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235PubMedCrossRefGoogle Scholar
  62. Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Rainer H. Böger
    • 1
  • Gerhard Schmidt
    • 2
  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHamburg
  2. 2.Institut für Pharmakologie und ToxikologieUniversitätGöttingen

Personalised recommendations